WIXOM, Mich.– Rockwell Medical, Inc. (the “Company”) (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that Tim Chole was promoted to Chief Commercial Officer, reporting to the Company’s President and CEO, Dr. Mark Strobeck.
Mr. Chole joined Rockwell Medical in December 2019 as SVP, Sales and Marketing. In November 2022, following the Company’s new business strategy announcement, Mr. Chole led Rockwell’s commercial organization and supported the Company’s vision to focus its efforts on enhancing its revenue-generating businesses and driving the Company towards profitability.
“Tim has an exceptional track record successfully building renal care portfolios and significantly growing sales at some of the largest renal care companies in the world,” said Mark Strobeck, Ph.D., President and CEO at Rockwell Medical. “Tim has played a key role in helping us increase our market share, broaden our product portfolio, right-size our pricing, improve our gross margins, and achieve record net sales quarter-over-quarter and year-over-year. I am thrilled to be working alongside Tim at this key juncture in Rockwell’s history as we aim to continue to grow our business through organic and inorganic growth and other business development opportunities that support our strategic objectives.”
“Customers want to work with Rockwell because we are dedicated to providing the highest quality products supported by the best customer service in the industry,” said Mr. Chole. “I am excited by the progress that we have made and the opportunities that lie ahead for Rockwell. It is a privilege to help steward the commercial future of this organization as we strive to positively impact more vulnerable patients with end-stage kidney disease.”
Mr. Chole has more than 20 years’ experience in commercial leadership roles for pharmaceutical and medical device companies. He has a proven track record of success launching products and growing mature portfolios, many of which have been therapeutics or devices for treatment of renal disease. Early in his career, Mr. Chole served as the marketing lead for the IV iron portfolio at Watson Pharmaceuticals (now Allergan), and later was the Global Marketing Director for AKI Therapy at Gambro AB (now Baxter International Inc.). Mr. Chole’s background includes global and U.S. marketing leadership and market development roles. Prior to joining Rockwell Medical, Mr. Chole served as the Director of Product Marketing and Professional Education for hearing implants at Cochlear Americas. Mr. Chole received a Bachelor of Science degree in managerial economics from the University of California at Davis.
